e-learning
resources
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy
Guy Brusselle, Janice Canvin, Sivan Weiss, Shawn X. Sun, Roland Buhl
Source:
ERJ Open Res, 3 (3) 00004-2017; 10.1183/23120541.00004-2017
Journal Issue:
July
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Guy Brusselle, Janice Canvin, Sivan Weiss, Shawn X. Sun, Roland Buhl. Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy. ERJ Open Res, 3 (3) 00004-2017; 10.1183/23120541.00004-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016
Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
SQ HDM SLIT-tablet is effective in patients not well-controlled in GINA treatment steps 2-4
Source: International Congress 2016 – Asthma management
Year: 2016
10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab.
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
Characteristics of the uncontrolled asthmatic patients on GINA step 4 treatment in Korea
Source: Annual Congress 2012 - Epidemiology of asthma
Year: 2012
Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021
Year: 2021
Clinical experience with montelukast plus ICS vs. only ICS in non-asthmatic eosinophilic bronchitis (NAEB) in Indian patients
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Adherence to the treatment of patients with bronchial asthma
Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage?
Year: 2015
Follow-up of patients with moderate-severe allergic asthma treated with omalizumab
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial
Source: Annual Congress 2011 - New treatments for airway disease
Year: 2011
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment?
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Characteristics of asthma patients responding to anti-IgE therapy
Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Year: 2013
Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Study of the Glutoxim-containing inhalation treatment in bronchial asthma patients
Source: Eur Respir J 2002; 20: Suppl. 38, 373s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept